The future of salvage lymph node dissection in the prostate-specific membrane antigen era
- PMID: 34708526
- DOI: 10.1111/bju.15591
The future of salvage lymph node dissection in the prostate-specific membrane antigen era
Comment on
-
Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).BJU Int. 2021 Sep;128(3):301-303. doi: 10.1111/bju.15485. Epub 2021 Jun 4. BJU Int. 2021. PMID: 34021954 No abstract available.
References
-
- Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-16
-
- Bravi CA, Fossati N, Gandaglia G et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol 2020; 78: 661-9
-
- Maurer T, Gschwend JE, Eiber M. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases. Curr Opin Urol 2018; 28: 191-6
-
- Luiting HB, van Leeuwen PJ, Busstra MB et al. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int 2020; 125: 206-14
-
- Knipper S, Tilki D, Graefen M, Maurer T. Early prostate cancer recurrence with prostate-specific membrane antigen positron emission tomography positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579). BJU Int 2021; 128: 301-3
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources